6th ELCC, Geneva, April, 2016 The IASLC Proposals for the 8th Edition of TNM in Lung Cancer: <u>Stages and Therapeutic</u> <u>Implications?</u>

Peter Goldstraw,



Honorary Consultant in Thoracic Surgery, Royal Brompton Hospital, London, UK. Emeritus Professor of Thoracic Surgery, Imperial College, London, UK. Past-President, IASLC.




DISCLOSURE SLIDE

The speaker has no disclosures to make in connection with this presentation.



EUROPEAN LUNG CANCER CONFERENCE 2016

Tree based on 25,911 M0 Training Cases, best stage



T1aN0 T1b2N0


Terminal Node Groups

HR relative to left-most node


Terminal Node		STRATIFIED							
Group	Events/N	HR*	7 th Ed.	Proposal 1	Proposal 2	Proposal 3	Proposal 4	Proposal 5	Proposal 6
T1aN0	126/1223	1.00	IA	IA	IA	IA1	IA1	IA1	IA 1
T1bN0	637/4140	1.55	IA	IA	IA	IA2	IA2	IA2	IA 2
T1cN0	624/3098	2.07	IA	IA	IA	IA3	IB1	IB1	IA3
T2(3-4)N0	1157/4315	2.83	IB	IB	IB	IB1	IB1	IB1	IB
T2(4-5)N0	393/1137	3.90	IB	IB	IIA	IB2	IB2	IB2	IIA
T2(5-7)-T3 N0	797/1968	5.07	IIA/IIB	IIA	IIB	IIA	IIA	IIA	IIB
T1-T2 (4-5cm) N1	737/1755	5.09	IIA	IIA	IIB	IIA	IIA	IIA	IIB
T2(5-7)-T3 N1	296/558	7.56	IIB/IIIA	IIB	IIIA	IIB	IIB	IIB	IIIA
T1-T2(4-5) N2	1192/2226	7.82	IIIA	IIB	IIIA	IIB	IIB	IIIA	IIIA
T3(>7)-T4 N0-1	1669/2459	10.10	IIIA/IIIB	IIB	IIIA	IIC	IIIA	IIIA	IIIA
T1-T2(4-5) N3	82/126	14.09	IIIB	IIIA	IIIB	IIIA	IIIB	IIIB	IIIB
T2(5-7)-T4 N2	1648/2229	14.34	IIIA/IIIB	IIIA	IIIB	IIIA	IIIB	IIIB	IIIB
T2(5-7)-T4 N3	581/677	21.73	IIIB	IIIB	IIIB	IIIB	IIIC	IIIC	IIIC

*Splitting algorithm uses stratified tests, and the HRs are calculated based on stratified model. Stratification factor is type of database submission (registry vs. other).

Proposal 6 Clinical Stage (training set)




Proposal 6 Pathologic Stage (training set)



			24	60
	Events / N	MST	Month	Month
A1	105 / 985	NR	96%	90%
A2	568 / 3821	NR	94%	84%
A3	579 / 2960	NR	92%	80%
B	1094 / 4144	NR	<mark>89%</mark>	73%
IA	373 / 1098	NR	83%	65%
IB	1445 / 3518	NR	77%	56%
IIA	2143 / 3862	42.0	65%	41%
IIB	815 / 1172	22.0	47%	24%
IIC	38 / 47	10.5	31%	12%

Validation Set Proposal 6; Best Stage



Proposed Stage Groups (1). Stage IA (1-3) T1a-c, N0 MO Stage IB **MO T2a**, NO Stage IIA T2b, N0 MO Stage IIB T3, N0 **M**0 T1-2, N1 MO Stage IIIA **T3**, **N1 MO NO-1** MO T4.

T1-2, N2

MO

Proposed Stage Groups (2). Stage IIIB T1-2, N3 $\mathbf{M0}$ T3-4, N2 **M0** Stage IIIC T3-4, N3 $\mathbf{M0}$ Stage IVA T any, N any M1a-b Stage IVB T any, N any M₁c

Proposed Stage Groupings for 8e

	NO		N1		N	12	N	13
	v7	New	v7	New	v7	New	v7	New
T1a	IA	IA1	IIA	IIB	IIIA	IIIA	IIIB	IIIB
T1b	IA	IA2	IIA	IIB	IIIA	IIIA	IIIB	IIIB
T1c	IA	IA3	IIA	IIB	IIIA	IIIA	IIIB	IIIB
T2a	1B	IB	IIA	IIB	IIIA	IIIA	IIIB	IIIB
T2b	IIA	IIA	IIB	ĬB	IIIA	ША	IIIB	IIIB
Т3	IIB	IIB	IIIA	IIIA	IIIA	IIIB	IIIB	IIIC
Τ4	IIIA	IIIA	IIIA	IIIA	IIIB	IIB	IIIB	IIIC
M1a	IV	IVA	IV	IVA	IV	IVA	IV	IVA
M1b	IV	IVA	IV	IVA	IV	IVA	IV	IVA
M1c	IV	IVB	IV	IVB	IV	IVB	IV	IVB

Tumour Size

Descriptor	T 7e	T 8e	NO	N1	N2	N3
Size >4 - 5cms	T2a		IB	IIA	IIIA	IIIB
		T2b	IIA	IIB	IIIA	IIIB
		T2b	ΠΑ	IIB	IIIA	IIIB

= change of stage due to change of T descriptor

Tumour Size

Descriptor	T 7e	T 8e	NO	N1	N2	N3
Size >5 - 7cms	T2b		IIA	IIB	IIIA	IIIB
		Т3	IIB	IIIA	IIIA	ШВ
		T3	IIB	IIIA	IIIB	шс

= change of stage due to change of T descriptor

= change of stage grouping in 8e

Tumour Size (and diaphragm invasion)

Descriptor	T 7e	T 8e	NO	N1	N2	N3
Size >7cms	Т3		IIB	IIIA	IIIA	IIIB
		T4	ΠΙΑ	IIIA	IIIB	IIIB
		T4	IIIA	IIIA	IIIB	IIIC

= change of stage due to change of T descriptor

= change of stage grouping in 8e

Bronchial Extent

Descriptor	T 7e	T 8e	NO	N1	N2	N3
Tumour < 2cms from carina, total atelectasis	T3		IIB	IIIA	IIIA	IIIB
		T2a	IB	IIA	IIIA	IIIB
		T2a	IB	IIB	IIIA	IIIB

= change of stage due to change of T descriptor

= change of stage grouping in 8e

The Health Warnings!

- These are at present only proposals!
- Stage does not dictate treatment.
 - The proposals reflect prognosis according to present treatment algorithms used in our data base.
 - Any changes in treatment algorithms should be based on *clinical judgement*, supported by *appropriate trials*.

Implications (1)

Proliferation of size cut-point:

Encourage debate on measurement of size, especially GGO/Mixed lesions.

T1a-c split in N0 cases:

Implications for structured surveillance in screening programmes, (8-9% fall in 5-yr survival for each 1 cm).

Refine sub-groups in studies of sub-lobar resection/SABR/RFA in small node negative cancers.

Implications (2)

Additional groups for adjuvant chemotherapy?

- Tumours >4 5cms, N0, (IB to IIA).
- Tumours >5 7cms, N0, (IIA to IIB).
- Tumours > 7cms, N0 (IIB to IIIA).
- Diaphragm invasion, N0, (IIB to IIIA).

- Greater emphasis on adjuvant chemotherapy in R0 cases, possibly to induction chemotherapy:
 - Tumours 0 4 cms, N1, (IIA to IIB).
 - Tumours 5 7 cms, N1, (IIB to IIIA).

Implications (3)

Strengthen argument against surgery:
 Tumours >5cms or with diaphragm invasion,
 T3/T4 associated with N2, (IIIA to IIIB).
 T3/T4 associated with N3, (IIIB to IIIC).

- Less emphasis on adjuvant chemotherapy following R0 resection:
 - Tumours < 2 cms from carina/total atelectasis, N0, (IIB to IB).

Implications (4)

- Stronger argument for surgery + adjuvant chemotherapy:
 - Tumours < 2 cms from carina/total atelectasis, associated with N1 disease, (IIIA to IIB).

- New divisions of M1 disease, Stage IVA/B:
 - Encourage greater use of local therapies, including surgery in conjunction with systemic treatment in M1b, oligometastatic disease.

8th Edition of TNM

- All proposals have been published in JTO
 Free to non-members of IASLC.
- IASLC has submitted proposals to UICC/AJCC on Lung Cancer, Thymic malignancies and Mesothelioma July/August 2015.
- Publication presently scheduled for late 2016 (WCLC 2016 in Vienna).
- IASLC educational products available at WCLC Vienna, free/discounted for members.
- **To be enacted January 2017.**

INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER





IASLC 17TH WORLD CONFERENCE ON LUNG CANCER

DECEMBER 4-7, 2016 VIENNA, AUSTRIA

IASLC-

INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER

ROBERT PIRKER, MD

CONFERENCE PRESIDEN

III II

*** *** *** *** *** ***

WWW.IASLC.ORG

1077

SAVE THE DATE!